#16 Aina Oliver-Caldés: Academic CAR-T cells for myeloma

https://is1-ssl.mzstatic.com/image/thumb/Podcasts116/v4/0c/68/f6/0c68f694-4619-b07b-514f-f1f24381ecf4/mza_11527742438603350550.jpg/600x600bb.jpg

Trainee Pearls

The EBMT Trainee Committee

16 episodes

2 days ago

Welcome to “Trainee Pearls”, a new initiative brought to you by the EBMT Trainee Committee to deliver the most important messages (“the pearls”) of high-profile research works in hematology and bone marrow transplant to our fellow trainees all over the world. The topics will span from classical hematology to more focused bone marrow transplant research. The selected research article will be discussed directly with young authors who have been involved with the published work.

Medicine

Health & Fitness

RSS

All content for Trainee Pearls is the property of The EBMT Trainee Committee and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded/19621461/19621461-1637602937949-a7c1eda9a2c1c.jpg

#16 Aina Oliver-Caldés: Academic CAR-T cells for myeloma

Trainee Pearls

17 minutes 17 seconds

2 years ago

#16 Aina Oliver-Caldés: Academic CAR-T cells for myeloma

Chimeric antigen receptor (CAR) T-cell therapy is a promising option for patients with heavily treated multiple myeloma. Point-of-care manufacturing can increase the availability of these treatments worldwide. Aina and colleagues assessed the safety and activity of ARI0002h, a BCMA-targeted CAR T-cell therapy developed by academia, in patients with relapsed or refractory multiple myeloma. https://pubmed.ncbi.nlm.nih.gov/37414060/ ALSO AS VIDEO ON https://youtu.be/Ymgg22roWGU CONNECT WITH US https://twitter.com/TheEBMT_Trainee https://www.ebmt.org/trainee-committee https://twitter.com/CarmeloGurnari